What Is PT-141?
PT-141 (Bremelanotide) is a synthetic peptide that activates melanocortin receptors in the brain — specifically MC3R and MC4R — to enhance sexual arousal and libido. Unlike medications that work through vascular mechanisms (such as sildenafil or tadalafil), PT-141 acts centrally on the nervous system to increase sexual desire at the brain level rather than simply enabling physical response.
FDA Approval Status
A prescription version of bremelanotide (Vyleesi) was FDA-approved in June 2019 specifically for hypoactive sexual desire disorder (HSDD) in premenopausal women. This makes it distinct from most other research peptides — there is an FDA-approved pharmaceutical version, though the research peptide PT-141 sold online is not the same regulated product.
Why It Is Relevant to GLP-1 Users
Weight loss and hormonal changes associated with GLP-1 therapy can affect sexual function in multiple directions. Some users report improvements in libido as metabolic health improves and weight-related self-image issues resolve. Others experience temporary decreases in libido during the early adjustment period, potentially related to calorie restriction, hormonal shifts, or the general physical adjustment to the medication.
Administration
PT-141 is administered as a subcutaneous injection, typically 45 minutes to 2 hours before the desired effect. The prescription version (Vyleesi) comes in a pre-filled auto-injector for self-administration. Common side effects include nausea, flushing, and headache — which limits its use for some patients.
Considerations
If sexual health changes are a concern during GLP-1 therapy, discussing this directly with your prescribing physician is the appropriate first step. A licensed provider can evaluate the cause, consider relevant options including Vyleesi when appropriate, and address the issue in the context of your overall health picture.